Status: Not yet recruiting
Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational Study
This is a cross-sectional, observational, multi-center study to assess the prevalence of inhibitor development in hemophilia A patients receiving Coageight (rFVIII-Fc, AryoGen Pharmed Co.).
Participants needed: 262
Trial details
Age: 2+Biological sex: MaleType: ObservationalSponsor: AryoGen Pharmed Co.Updated: Aug 28, 2026Locations: 6
Eligibility criteria
Male patients aged 2 years or older with a signed informed consent by them or th... [+2]
History of any other coagulation disorders except hemophilia A and disorders rel... [+3]